Fidelity Investments’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
Fidelity Investments's AVTX Position: Q3 2026 in Review
Fidelity Investments increased its Avalo Therapeutics (AVTX) stake by 2.9% in Q3 2026, buying an estimated $2.76M and bringing the position to 5,250,181 shares worth $80.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1296.
Fidelity Investments first reported a position in AVTX in Q2 2024 and has held it in 6 quarters since. The position peaked at $94.3M in Q2 2026. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.
- Fidelity Investments held 5,250,181 shares of Avalo Therapeutics worth $80.5M as of Q3 2026.
- Fidelity Investments bought 149,965 Avalo Therapeutics shares in Q3 2026, an estimated $2.76M.
- Avalo Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #1296 holding.
- Fidelity Investments first reported a position in Avalo Therapeutics in Q2 2024 and has held it in 6 quarters since.
- Fidelity Investments's Avalo Therapeutics position peaked at $94.3M in Q2 2026.
- 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.
Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.